IOBT beat EPS expectations by 60.67%
Nov 16, 2025, 11:38 AM
0.00%
What does IOBT do
IO Biotech develops immune-modulating cancer therapies using its Twin technology platform, targeting tumor-induced immunosuppression. Its lead candidate, IO102-IO103, addresses key proteins IDO and PD-L1.
IO Biotech (IOBT) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, IO Biotech's actual EPS was -$0.13, beating the estimate of -$0.33 per share, resulting in a 60.67% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.